TC
PCRX icon

TwinBeech Capital’s Pacira BioSciences PCRX Stock Holding History

TwinBeech Capital’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-54,274
Closed -$1.55M – 836
2024
Q2 		$1.55M Sell
54,274
-30,444
-36% -$866K 0.03% 356
2024
Q1 		$2.48M Buy
+84,718
New +$2.6M 0.05% 314
2023
Q2 		– Sell
-36,751
Closed -$1.5M – 797
2023
Q1 		$1.5M Sell
36,751
-73,027
-67% -$2.91M 0.03% 410
2022
Q4 		$4.24M Buy
+109,778
New +$5.34M 0.08% 289
2021
Q3 		– Sell
-10,026
Closed -$608K – 713
2021
Q2 		$608K Buy
+10,026
New +$635K 0.07% 283
2020
Q4 		– Sell
-3,539
Closed -$213K – 571
2020
Q3 		$213K Buy
+3,539
New +$206K 0.05% 385

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

TwinBeech Capital's PCRX Position: Q3 2024 in Review

TwinBeech Capital sold out of Pacira BioSciences (PCRX) in Q3 2024, closing a stake of 54,274 shares — an estimated $1.55M sold.

TwinBeech Capital first reported a position in PCRX in Q3 2020 and held it in 6 quarters. The position peaked at $4.24M in Q4 2022. 239 funds tracked by Wall St. Rank hold PCRX as of Q3 2024.

  • TwinBeech Capital reported no remaining Pacira BioSciences position as of Q3 2024 after selling out during the quarter.
  • TwinBeech Capital sold 54,274 Pacira BioSciences shares in Q3 2024, an estimated $1.55M.
  • TwinBeech Capital first reported a position in Pacira BioSciences in Q3 2020 and held it in 6 quarters.
  • TwinBeech Capital's Pacira BioSciences position peaked at $4.24M in Q4 2022.
  • 239 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2024.

Based on TwinBeech Capital's 13F filing for Q3 2024, filed 14 Nov 2024.